Literature DB >> 11790660

Protection from pulmonary fibrosis in leukotriene-deficient mice.

Marc Peters-Golden1, Marc Bailie, Teresa Marshall, Carol Wilke, Sem H Phan, Galen B Toews, Bethany B Moore.   

Abstract

Although overproduction of proinflammatory 5-lipoxygenase (5-LO)-derived leukotrienes (LTs) has been demonstrated in the lungs of patients with pulmonary fibrosis, their causal involvement in this condition has not been established. Bleomycin-induced pulmonary fibrosis was studied in mice rendered LT deficient by knockout of the 5-LO gene (KO) and in wild-type (WT) control mice. Following administration of bleomycin, lung lavage fluid of WT mice demonstrated an approximately 5-fold increase in levels of cysteinyl-LTs over baseline levels at Day 1, with persistent elevation up to Day 21. As compared with WT mice, 5-LO KO mice demonstrated reduced amounts of histologically evident collagen as well as an approximately 60% reduction in lung hydroxyproline levels postbleomycin. Unlike WT mice, KO mice showed no increases in the numbers of lung inflammatory cells postbleomycin. Furthermore, in situ expression and stimulated production by mixed lung leukocytes of the antifibrotic cytokine interferon-gamma were significantly greater in cells from the 5-LO KO mice. Finally, lavage levels of the antiinflammatory and antifibrotic molecule, prostaglandin E(2), were significantly greater in the KO animals. These results provide strong evidence that LTs may participate in the pathogenesis of pulmonary fibrosis, and they may do so by direct effects as well as indirect effects occurring via their modulation of the synthesis of other inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790660     DOI: 10.1164/ajrccm.165.2.2104050

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

Review 1.  Disorders of lung matrix remodeling.

Authors:  Harold A Chapman
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 4.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

5.  Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells.

Authors:  S Brandon Early; Elizabeth Barekzi; Julie Negri; Kathleen Hise; Larry Borish; John W Steinke
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

Review 6.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

7.  SARS-CoV regulates immune function-related gene expression in human monocytic cells.

Authors:  Wanchung Hu; Yu-Ting Yen; Sher Singh; Chuan-Liang Kao; Betty A Wu-Hsieh
Journal:  Viral Immunol       Date:  2012-08       Impact factor: 2.257

8.  Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.

Authors:  Toru Oga; Toshiyuki Matsuoka; Chengcan Yao; Kimiko Nonomura; Shiho Kitaoka; Daiji Sakata; Yoshihiro Kita; Kiminobu Tanizawa; Yoshio Taguchi; Kazuo Chin; Michiaki Mishima; Takao Shimizu; Shuh Narumiya
Journal:  Nat Med       Date:  2009-11-29       Impact factor: 53.440

9.  Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.

Authors:  Thomas C Beller; Daniel S Friend; Akiko Maekawa; Bing K Lam; K Frank Austen; Yoshihide Kanaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

10.  A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yuanjue Zhu; Yong Liu; Weixun Zhou; Ruolan Xiang; Lei Jiang; Kewu Huang; Yu Xiao; Zijian Guo; Jinming Gao
Journal:  Respir Res       Date:  2010-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.